icon-charity icon-donate-car icon-energy icon-fundraise icon-shop icon-sponsorships

phase 1

clinical trial

can T cell immunotherapy work in osteosarcoma and nb?

Project Title: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcomas
Researcher: Lawrence Lum, PhD
Institution: Karemanos Cancer Center; Memorial Sloan-Kettering Cancer Center
Study Type: Phase 1 Clinical Trial
Status: Opening in 2015

Summary: This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neurblastoma, osteosarcoma, and other GD2+ solid tumors.

Impact: This study will provide new information on whether infusions of these activated T cells will not only kill the tumor but also "vaccinate" the patients against their own cancer resulting in significant improvement in survival for patients with relapsed GD2-positive tumors.

more clinical trials

Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase9 Suicide Safety Switch for Neuroblastoma

Read More >

Improving GD2 T cell Immunotherapy for Patients with Neuroblastoma

Read More >